AMYOTROPHIC LATERAL SCLEROSIS (ALS)

This phase 3 trial tests whether adding masitinib to standard ALS treatment (riluzole) can slow the loss of physical function better than placebo plus riluzole. About 412 adults with ALS will take the drug or placebo for 48 weeks. The main goal is to measure changes in daily abil…

This early-stage trial tests whether a dietary supplement called HMB is safe and can slow the progression of ALS. About 100 adults with ALS will take HMB and be monitored for changes in function and blood markers. The goal is to see if HMB can lower certain proteins linked to ner…

This study tests whether starting breathing support (non-invasive ventilation) early can help people with ALS who are not yet severely weak. Researchers will use a tool to predict who is at high risk of breathing problems within 6 months. 48 participants will either start early v…

This early-stage study tests a new gene therapy, SNUG01, in 21 adults with ALS. The main goal is to see if it is safe and tolerable when given via a spinal injection. Researchers will also look for early signs that it might slow the disease. This is not a cure, but aims to contro…

This study tests a new program called Resilient Together-ALS for people recently diagnosed with ALS and their caregivers. The program uses mind-body techniques to help manage emotional distress and build coping skills. About 20 patient-caregiver pairs will participate to see if t…

This study looks at whether giving people with ALS and their caregivers video recordings of their clinic visits helps them feel better and remember important information better than just getting written notes. About 800 participants (400 patient-caregiver pairs) from eight U.S. s…

This study uses ultrasound to measure how non-invasive ventilation (NIV) changes diaphragm movement in people with ALS. Twenty adults who need NIV will have their diaphragm motion and thickness measured during normal breathing and while using the ventilator. The goal is to see if…